Aktienanalyse zu MBX Biosciences Inc (MBX)MBXMBX Biosciences Inc

MBX Biosciences, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP platform, for the treatment of endocrine and metabolic disorders. It is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets and proven endpoints for regulatory approval. Its pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism in Phase III development and an obesity portfolio that includes MBX 4291 in Phase I development and MBX 5765 and MBX 6180 in preclinical development, as well as additional discovery candidates. Its lead obesity product candidate, MBX 4291, is designed to be a long-acting and highly potent glucagon-like peptide 1 (GLP-1) / glucose-dependent insulinotropic polypeptide (GIP) co-agonist prodrug with the goal of potential once-monthly dosing frequency. It operates in the Healthcare sector.

MBX Biosciences is currently a hold. The stock is priced at $49.61, significantly below analyst price targets, with Stifel at $84 and Guggenheim at $150, indicating potential upside. However, the RSI is at 29.48, suggesting it is oversold, and the company reported a net loss of $37.1 million in Q2 2026, which raises concerns about profitability. The main risk is the declining financial performance, as evidenced by a 21.14% drop over the last 20 days and a disappointing EPS of -0.78 in the last quarter.